Uncategorized
Analysis of Pooled Data from TEPEZZA® (teprotumumab-trbw) Clinical Trials Reinforces Safety Profile in People with Thyroid Eye Disease (TED)
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced results of a new analysis examining rates of hyperglycemia among patients treated with TEPEZZA for TED compared to placebo in the Phase 2 and OPTIC Phase 3 clinical trials. These results were presented as part of the annual conference of the Endocrine Society, ENDO 2022, June 11-14 in Atlanta, Georgia. Data will also be published in a supplemental issue of the Journal of the Endocrine Society. TEPEZZA is the first